Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02071862
Title Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Calithera Biosciences, Inc
Indications

lung non-small cell carcinoma

gastrointestinal stromal tumor

triple-receptor negative breast cancer

renal cell carcinoma

malignant mesothelioma

Advanced Solid Tumor

Therapies

Everolimus + Telaglenastat

Erlotinib + Telaglenastat

Docetaxel + Telaglenastat

Telaglenastat

Paclitaxel + Telaglenastat

Cabozantinib + Telaglenastat

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST